Haemophilus influenzae type b Conjugate Vaccine Impact Against Purulent Meningitis in Rwanda
Rwanda introduced Haemophilus influenzae type b (Hib) conjugate vaccine in January 2002 and simultaneously implemented pediatric bacterial meningitis surveillance at a major referral hospital in the capital Kigali. This study reviewed clinical and laboratory information collected during January 2002 to June 2006 and determined that in an African setting with few resources and in which few confirmed Hib meningitis cases were identified, Hib vaccine impact nevertheless could be demonstrated against the outcome of purulent meningitis and was found to be high. This article was published in Vaccine.
Author: Muganga N, Uwimana J, Fidele N, et al.
» Visit web page (English)
(Located at www.sciencedirect.com)
Citation: Muganga N, Uwimana J, Fidele N, et al. Haemophilus influenzae type b Conjugate Vaccine Impact Against Purulent Meningitis in Rwanda. Vaccine. 2007:25(39-40):7001-7005.
Resource types: Peer-reviewed journal
Diseases/vaccines: Haemophilus influenzae type b (Hib)